LGR5 expression predicts peritoneal recurrence after curative resection of primary colon cancer.
By: Hiroshi Nagata, Soichiro Ishihara, Hiroyuki Abe, Tetsuo Ushiku, Junko Kishikawa, Toshiaki Tanaka, Keisuke Hata, Kazushige Kawai, Masashi Fukayama, Hiroaki Nozawa

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan. hinagata-tky@umin.ac.jp.
2018-03-09; doi: 10.1038/s41416-019-0442-5
Abstract

Background

The aim of this study was to clarify whether a cancer stem cell marker could be an indicator of post-operative peritoneal recurrence of colon cancer.

Methods

Expression of four putative markers (CD133, CD44 variant 6, aldehyde dehydrogenase-1 and leucine-rich repeating G-protein-coupled receptor-5 (LGR5)) was evaluated immunohistochemically in primary tumour samples from 292 patients who underwent curative resection for non-metastasised pT4 colon cancer at the University of Tokyo Hospital between 1997 and 2015.

Results

Peritoneal recurrence was significantly higher in LGR5-negative cases (5-year cumulative incidence: 27.5% vs. 14.4%, p = 0.037). Multivariable analysis confirmed that negative LGR5 expression was an independent risk factor for peritoneal recurrence (hazard ratio (HR) 2.79, p = 0.005) in addition to poor differentiation, positive lymph node metastasis, preoperative carcinoembryonic antigen > 5 ng/mL and anastomotic leakage. The addition of LGR5 significantly improved the predictive value of the multivariable model (net reclassification improvement: 0.186, p = 0.028: integrated discrimination improvement: 0.047, p = 0.008).

Conclusions

Negative LGR5 expression was a significant predictor of peritoneal recurrence in patients with pT4 colon cancer. Therefore, LGR5 might be a promising biomarker to identify patients at high risk of post-operative peritoneal metastasis.





PMID:31000786






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements